Parkinson's Life
Support us

  • Voices
    • Interviews
    • Perspectives
  • Wellbeing
    • Health & Fitness
    • Recipes & Nutrition
    • Resources & Tools
    • Carers’ Corner
  • Campaigns
    • Europe
    • Global update
    • In my country
    • Women and Parkinson’s
  • Research
    • Advances
    • Special reports
    • PD in Practice
  • Podcasts
    • Episodes
Subscribe Support us
Joanne Clements part two lead

Perspectives

Misdiagnosed with Parkinson’s: why access to specialist neurologists is essential

What happens when your Parkinson’s diagnosis is actually wrong

READ MORE

Perspectives

Doctors thought I had Parkinson’s for nearly a decade – they were wrong

What’s it like to think you had Parkinson’s for nearly…

READ MORE

There are 2 results for "Joanne Clements" in "All"

MOST READ RECENT ARTICLES

Christmas gifts for people with Parkinson's

5 Christmas gifts for people with Parkinson’s

“Look at us – we are here”

The dark side of Parkinson's film series

“The darker aspects of Parkinson’s are rarely discussed”

An older woman receives a vaccine

Coronavirus vaccines: key facts for people with Parkinson’s disease

TV legend Des O’Connor privately lived with Parkinson’s disease

IN THE NEWS

Carefully selected news stories from the international Parkinson's community.

4 days ago

New biotech to drive forward GDNF treatment for Parkinson’s disease

UK charity Parkinson’s UK is creating a new company, Vivifi Biotech, to develop a treatment with potential to stop or reverse Parkinson’s disease. The experimental therapy surgically distributes GDNF, a protein that is naturally produced by the brain to protect cells, directly into the brain. The charity previously funded a clinical trial to investigate whether boosting GDNF levels could regenerate dying brain cells in people with Parkinson’s. Over the next two years, it will invest up to £800,000 to prepare for a second trial. Arthur Roach, head of research at Parkinson’s UK, said: “While our initial trial didn’t meet its critical endpoint, it did reveal robust evidence indicating that GDNF can possibly reverse Parkinson’s. This is why Parkinson’s UK is committed to continuing research into this potential treatment.” Vivifi Biotech, Roach added, will “bring the right people together to plan a new trial that meets the needs of patients, regulatory…

Read more
2 weeks ago

New wearable medical device for Parkinson’s disease to launch this year

The Imperial College London Innovation Fund, UK, has invested £205,000 to support UK-based tech company Charco Neurotech in its development of a non-invasive medical device for people with Parkinson’s disease. CUE1, a circular device that attaches to the sternum with medical adhesives, uses specialised vibration to help alleviate physical symptoms of Parkinson’s disease. Initial user testing among people with the condition found that the device improved movement by an average of 16%, with testers reporting benefits for walking and fine motor tasks. Lucy Jung, CEO and co-founder of Charco Neurotech, said: “We believe that CUE1 has the potential to significantly improve [Parkinson’s disease] symptoms through its unique controlled vibration technology. We are excited to continue our work on the device and we look forward to the outcome of our proposed clinical trials.” Charco Neurotech will use the Imperial College investment to initiate a clinical trial and fund the device’s manufacture for…

Read more
3 weeks ago

New study brings scientists a “vital step” closer to understanding Parkinson’s disease

A new study from scientists at the University of Cambridge, UK, has brought researchers “a vital step” closer to discovering the origins of Parkinson’s disease. The research, published in the scientific journal ‘Nature Communications’, offered insights on the protein alpha-synuclein, which clumps together in the neurons of people with Parkinson’s. The study focused on how the protein functions in those without the condition and revealed that it sticks to the inner side of the plasma membrane of nerve cells, but not the outer membrane – an insight that could help in the search for a cure. Lead study author, Dr Giuliana Fusco, said: “This study could unlock more information about this debilitating neurodegenerative disorder that can leave people unable to walk and talk. If we want to cure Parkinson’s, first we need to understand the function of alpha-synuclein, a protein present in everyone’s brains.”

Read more
LOAD MORE NEWS
{time}

{title}

{excerpt} {rl_text}
  • Contact us
  • About
  • Support us
  • Privacy Policy
  • Disclaimer
  • Terms
Back to top
© Parkinson's Life 2021. All right reserved.

Subscribe

All fields required
  • This field is for validation purposes and should be left unchanged.
Terms and Privacy Policy

Sign in

forgot password? New to the site?
Create an account.